

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently Amended) A method for promoting structural tissue regeneration of the liver after surgical liver resection in an individual having a benign or malignant liver tumor, the method comprising systemically or topically administering to said individual ~~contacting the tissue with~~ erythropoietin (EPO), EMP, or novel erythropoiesis stimulating protein (NESP).

2. (Cancelled)

3. (Previously Presented) The method according to Claim 1, characterized by the use of the receptor-binding domain of EPO.

4. (Cancelled)

5. (Currently Amended) The method according to Claim 1, characterized in that the EPO, EMP, or NESP ~~have~~ has additional glycosylation sites compared with the native growth factor.

6. (Currently Amended) The method according to Claim 1, characterized in that the EPO, EMP, or NESP ~~are~~ is conjugated with PEG.

7-11. (Cancelled)

12. (Currently Amended) The method according to Claim 1, characterized in that the factor EPO, EMP, or NESP is administered topically.

13. (Currently Amended) The method according to Claim 1 ~~or 8~~, characterized in that the factor EPO, EMP, or NESP is administered systemically.

14-35. (Cancelled)

36. (Currently Amended) A method for ~~wound healing or liver regeneration, the method comprising administering to a patient a pharmaceutical composition according to Claim 34 of burn wounds in an individual using a skin graft without the occurrence of~~ scarring, the method comprising topically administering to said individual EPO, EMP, or NESP.

37. (New) The method of claim 13, wherein the EPO, EMP, or NESP is administered after surgical resection in an amount of 100-150 IU/kg of body weight.

38. (New) The method according to Claim 36, characterized by the use of the receptor-binding domain of EPO.

39. (New) The method according to Claim 36, characterized in that the EPO, EMP, or NESP has additional glycosylation sites compared with the native growth factor.

40. (New) The method according to Claim 36, characterized in that the EPO, EMP, or NESP is conjugated with PEG.